Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Amphotericin (lipid formulation) 50mg powder for infusion solution vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Amphotericin B liposome (substance) |
Inferred relationship |
Some |
|
Product containing amphotericin B liposome |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Amphotericin B liposome (substance) |
Inferred relationship |
Some |
|
Amphotericin (lipid formulation) 100mg powder for infusion solution vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Amphotericin B liposome (substance) |
Inferred relationship |
Some |
|
Amphotericin (lipid formulation) 5mg/mL suspension for injection 20mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Amphotericin B liposome (substance) |
Inferred relationship |
Some |
|
Amphotericin (lipid formulation) 5mg/mL suspension for injection 10mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Amphotericin B liposome (substance) |
Inferred relationship |
Some |
|
Product containing amphotericin B liposome in parenteral dosage form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Amphotericin B liposome (substance) |
Inferred relationship |
Some |
|
Amphotericin B phospholipid complex (substance) |
Is a |
False |
Amphotericin B liposome (substance) |
Inferred relationship |
Some |
|
Product containing only amphotericin B liposome (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Amphotericin B liposome (substance) |
Inferred relationship |
Some |
1 |
Amphotericin B liposome only product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Amphotericin B liposome (substance) |
Inferred relationship |
Some |
1 |
Amphotericin B cholesteryl sulfate complex (substance) |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Amphotericin B liposome (substance) |
Inferred relationship |
Some |
|
Amphotericin B phospholipid complex (substance) |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Amphotericin B liposome (substance) |
Inferred relationship |
Some |
|
Amphotericin B lipid complex (substance) |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Amphotericin B liposome (substance) |
Inferred relationship |
Some |
|
Amphotericin B liposome 5 mg/mL solution for injection |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Amphotericin B liposome (substance) |
Inferred relationship |
Some |
1 |
Amphotericin B liposome 5 mg/mL solution for injection |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Amphotericin B liposome (substance) |
Inferred relationship |
Some |
1 |
Amphotericin B liposome 50 mg powder for solution for injection vial |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Amphotericin B liposome (substance) |
Inferred relationship |
Some |
1 |
Amphotericin B liposome 50 mg powder for solution for injection vial |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Amphotericin B liposome (substance) |
Inferred relationship |
Some |
1 |